Tuesday, 31 Mar 2026
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • ScienceAlert
  • VIDEO
  • White
  • man
  • Trumps
  • Season
  • star
  • Watch
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Marvell’s tepid revenue forecast reignites AI spending fears, shares slump
Economy

Marvell’s tepid revenue forecast reignites AI spending fears, shares slump

Last updated: March 6, 2025 5:43 am
Share
Marvell’s tepid revenue forecast reignites AI spending fears, shares slump
SHARE

Marvell Technology Stock Tumbles Amid Concerns Over AI Infrastructure Spending

By Arsheeya Bajwa

(Reuters) – Marvell Technology experienced a significant 16% drop in its stock price on Thursday, causing a ripple effect across the chipmaker industry. The decline came after the company provided an in-line revenue forecast that raised concerns among investors about the outlook for spending on AI infrastructure. This downturn comes at a time when the long-standing rally in the sector is showing signs of cooling off.

Investors had been closely monitoring Marvell’s earnings, as the company is a crucial supplier of custom AI chips to major tech companies. The demand for these chips has been a driving force behind the market gains in the U.S. since the emergence of ChatGPT and the subsequent generative AI boom in late 2022.

Despite Marvell’s current-quarter revenue forecast being slightly above estimates by $10 million, concerns persist regarding the necessity of significant investments in AI infrastructure, particularly in light of cost-effective advancements made by Chinese startup DeepSeek.

The focus has now shifted to Broadcom, another key player in the custom AI chip space, whose results are expected later on Thursday. Marvell holds the second position in this market, with Broadcom being the most important supplier.

Following Marvell’s decline, shares of Broadcom fell by 4%, while Nvidia saw a 2% drop in its stock price.

The chip sector has also been impacted by the tariffs imposed by President Donald Trump on countries like China. The Philadelphia Semiconductor Index has experienced a 5% decline in 2025, following an impressive 20% gain the previous year.

See also  Joshua Allen's Girlfriend Shares Her Side of Viral Funeral Fight

Analysts from Melius Research commented on the current sentiment towards AI semiconductor stocks, noting that the negative reaction to Marvell’s performance was driven by a minor revenue beat and raise.

Marvell, which briefly surpassed Intel in market value last year, stands to lose $12 billion if premarket share losses are sustained. The stock saw a remarkable 83% increase in 2024 but has dipped by 18% so far in 2025.

Despite exceeding its fiscal 2025 target of $1.5 billion in AI revenue, Marvell anticipates surpassing its projections of $2.5 billion in AI sales for fiscal 2026, as mentioned by CEO Matt Murphy during a post-earnings call.

J.P. Morgan analysts attribute the subdued outlook to a slowdown in on-premise data center products, specifically citing weaker demand for ethernet cables and fiber channels used for data transfer across servers.

As major tech companies shift their focus towards AI chips, the demand for networking equipment, which constitutes Marvell’s core business, has weakened.

Custom chips typically yield lower margins compared to off-the-shelf processors, with Marvell expecting an adjusted gross margin of around 60% for the April quarter, down by more than two percentage points from the previous year.

Following the earnings report, at least nine brokerages have lowered their price targets for Marvell, with the median target at $130 according to LSEG data, representing a potential 44% upside from the stock’s last closing price.

(Reporting by Arsheeya Bajwa in Bengaluru; Editing by Sriraj Kalluvila)

TAGGED:FearsForecastMarvellsreignitesRevenueSharesSlumpspendingtepid
Share This Article
Twitter Email Copy Link Print
Previous Article Forget about your carbon footprint. Try ‘climatemaxxing.’ Forget about your carbon footprint. Try ‘climatemaxxing.’
Next Article A year later, OpenAI still hasn’t released its voice cloning tool A year later, OpenAI still hasn’t released its voice cloning tool
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Bipartisan support for federal research funding, and Dems sharpen arguments against Medicaid work requirements

The recent Senate hearing showcased bipartisan support for reversing the Trump administration's cuts to federally…

May 1, 2025

NFL fans react as Steelers elevate RB Trey Sermon to active roster

Kaleb Johnson's NFL journey started off on a rocky path with the Pittsburgh Steelers. In…

September 21, 2025

Earth’s days are getting longer. Climate change is to blame

The Earth's spin is slowing down due to the effects of climate change, causing days…

March 14, 2026

8 Sustainable Soap and Personal Care Brands

As consumers become more aware of the impact of their personal care products on the…

October 4, 2024

December’s Full Supermoon Rises Under Ideal Photography Conditions : ScienceAlert

The upcoming Supermoon event on December 4, 2025, promises to be a spectacular sight for…

December 2, 2025

You Might Also Like

Charlotte’s Web Q4 Earnings Call Highlights
Economy

Charlotte’s Web Q4 Earnings Call Highlights

March 31, 2026
Sysco Receives a Downgrade From Citi Due to Debt Load
Economy

Sysco Receives a Downgrade From Citi Due to Debt Load

March 31, 2026
Japan Post Insurance takes minority stake in KKR-backed group
Economy

Japan Post Insurance takes minority stake in KKR-backed group

March 31, 2026
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Economy

Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI

March 31, 2026
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?